News
Media
Conference
Publications
Resources
Partners
Subscribe

Spotlight -

Geographic Atrophy

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

Articles by Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, speaks about intermediated AMD risk markers and clinical endpoints at EURETINA 2025

EURETINA 2025: The changing face of clinical endpoints in AMD trials

ByRobyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS,Hattie Hayes,Sydney M Crago,Martin David Harp

September 19th 2025

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

Latest Updated Articles

Trending on Modern Retina

Eli Lilly to acquire Adverum Biotechnologies

Anti-VEGF innovations in retinal disease: From molecules to medicine

© 2025 MJH Life Sciences^®

All rights reserved.